Summary & Overview
HCPCS J0179: Brolucizumab Injection, Intravitreal, 1 mg
HCPCS Level II code J0179 denotes the administration of brolucizumab-dbll, 1 mg, delivered as an intravitreal injectable biologic therapy used in retinal disease management. This code captures a high-cost specialty ophthalmology drug administered in outpatient clinical settings and is relevant to payers managing utilization and coverage of novel ophthalmic biologics.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find national-level context on the code’s clinical role, commonly reported payer coverage types, and practical billing considerations. The publication outlines benchmarks for utilization and units billed where available, summarizes policy and coverage considerations that affect reimbursement workflows, and provides clinical context about the service model (intravitreal injection in outpatient ophthalmology settings).
This summary is intended for stakeholders across billing, clinical operations, and policy teams seeking a concise reference on HCPCS Level II code J0179 — what the code represents, typical sites of service, and the types of analyses and benchmarks included in the full publication. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J0179 represents injection, brolucizumab-dbll, 1 mg, a prescription ophthalmologic biologic administered via intravitreal injection for retinal disease management. The service type is an injectable biologic therapy delivered as an intravitreal injection. The typical site of service is an outpatient ophthalmology or retina clinic, ambulatory surgery center, or other outpatient setting equipped for intravitreal injections.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 72-year-old patient with neovascular (wet) age-related macular degeneration (nAMD) presents to the ophthalmology clinic for an intravitreal injection of brolucizumab-dbll (J0179, 1 mg). The patient has new or recurrent subretinal fluid and decreased visual acuity on review. Baseline assessment includes visual acuity, intraocular pressure measurement, slit-lamp exam, and dilated fundus exam. Optical coherence tomography (OCT) is performed immediately prior to injection to document retinal fluid. After informed consent, topical anesthesia and antiseptic preparation are applied in a dedicated procedure room or minor treatment area within the ophthalmology clinic. A single intravitreal injection of brolucizumab-dbll (J0179) is administered under sterile technique. Post-injection, the patient is observed for immediate adverse events, intraocular pressure is rechecked as needed, and follow-up is scheduled in 4–8 weeks for repeat assessment and potential retreatment. Typical site of service is an outpatient ophthalmology clinic or ambulatory surgical center (minor procedure area).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no special condition applies |
11 | Professional component | When only the physician’s professional component is billed (rare for injections) |
22 | Increased procedural services | When additional work or complexity beyond typical is documented |
23 | Unusual anesthesia | If an injection required general anesthesia or an unusual anesthetic approach |
52 | Reduced services | When the full service was not performed as described by the code |
53 | Discontinued procedure | If the procedure was started but terminated for patient safety |
55 | Postoperative management only | When only global postoperative care is being billed (uncommon for single injections) |
62 | Two surgeons | If two surgeons of different specialties actively perform portions of the service |
78 | Return to OR for related procedure during postoperative period | If a related surgical procedure is required emergently after the injection (rare) |
80 | Assistant surgeon | When an assistant surgeon participates in the procedure |
JW | Drug discarded/not administered to any patient | When part of the single-use vial is discarded and not administered (identifies discarded amount) |
JZ | No drug wastage | When no part of the single-use vial is discarded |
QX | CLIA waived test performed by non-credentialed staff | If a waived point-of-care test is performed by non-credentialed staff in conjunction with the visit |
QY | CLIA waived test performed by certified laboratory | If a waived point-of-care test is performed by certified personnel |
RT | Right side | When the injection is performed in the right eye |
LT | Left side | When the injection is performed in the left eye |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207W00000X | Ophthalmology | Retinal specialists commonly perform intravitreal injections |
207WP2900X | Retina/Vitreous Specialist | Subspecialists who manage neovascular retinal disease and administer injections |
208000000X | Optometry | Some optometrists with appropriate privileges may participate in co-management |
363L00000X | Ambulatory Surgery Center | Facility taxonomy for sites where injections may be performed in a minor procedure area |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
H35.32 | Exudative age-related macular degeneration | Primary indication for intravitreal brolucizumab therapy in neovascular AMD |
H35.31 | Nonexudative age-related macular degeneration | Differential diagnosis; may progress to exudative form requiring treatment |
H35.05 | Macular edema due to retinal vein occlusion | Off-label or related macular disease where intravitreal anti-VEGF agents may be used |
H34.8 | Other retinal vascular occlusions | Retinal vascular conditions that can cause macular edema treated with intravitreal agents |
H44.1 | Endophthalmitis | Serious complication of intravitreal injections; relevant for coding complications and follow-up |
H44.51 | Vitreous hemorrhage, right eye | Potential complication or comorbidity affecting treatment planning |
H44.52 | Vitreous hemorrhage, left eye | Potential complication or comorbidity affecting treatment planning |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
67028 | Intravitreal injection of a pharmacologic agent (separate procedure) | Primary procedure code for the intravitreal injection technique often billed alongside the drug HCPCS J0179 when the facility/professional split applies |
99212 | Office or other outpatient visit, established patient, low complexity | Pre- or post-injection evaluation for routine follow-up visits |
99213 | Office or other outpatient visit, established patient, moderate complexity | Typical office visit for assessment and decision to inject or manage complications |
92134 | Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report (e.g., OCT) | OCT imaging commonly performed before or after injection to document retinal anatomy and treatment response |
67036 | Vitrectomy, pars plana (for retinal surgery) | Related if a patient requires surgical management for complications such as endophthalmitis or retinal detachment |